cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.3535/zz0-bx5-081
title: Plantae

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/cmt-1xn-vws
title: Brachiopoda Duméril, 1805

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/mkn-fj2-tq2
title: Favosites pseudoforbesi ohesaarensi, Klaamann, 1962

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/flf-5nr-x6r
title: Plantae

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/pmc-2xb-26p
title: Brachiopoda Duméril, 1805

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/alm-f9y-vdr
title: Brachiopoda Duméril, 1805

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/w8e-l5r-cye
title: Plantae

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/ykw-8ds-91j
title: Brachiopoda Duméril, 1805

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/3z0-jfy-t5y
title: Plantae

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/b25-8mk-nq1
title: Brachiopoda Duméril, 1805

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/kxp-0p5-d5s
title: Brachiopoda Duméril, 1805

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/s41-hbf-ec7
title: Andreolepis petri Märss, 2001

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/ngq-8c1-vm1
title: sedimentary rocks

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/qm3-5ra-74w
title: Porifera Grant, 1836

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/kea-g3f-hq4
title: Andreolepis hedei Gross, 1968

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/km7-1wm-mmk
title: Calymenina

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/00h-xr7-zd9
title: sedimentary rocks

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/vwh-7t4-ebh
title: Calymenina

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/16c-qy8-16v
title: sedimentary rocks

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/9kg-s2a-yje
title: Siltstone

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/7k0-4kf-0tp
title: †Proetida

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/npw-7v8-m2q
title: †Trilobita

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/16q-f4w-str
title: †Trilobita

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/a35-gh0-rw8
title: Calymenina

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/c22-xgl-yyk
title: siliciclastic rocks

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.25934/pr00009268
title: A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa

description: The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
DOI: 10.3535/0bc-yaf-w6v
title: Neoasaphus

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/c2k-91j-llp
title: Neoasaphus

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.25934/00003759
title: A placebo controlled trial of alteplase (rt-PA) in acute ischemic hemispheric stroke where thrombolysis is initiated up to 6 hours following the onset of symptoms (ECASS-II)

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.3535/vb4-96c-4tg
title: †Trilobita

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.25934/00001220
title: A Multicenter, Trial Comparing the Efficacy and Safety of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily With Tiotropium 18 mcg Once Daily Over 24 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

description: The purpose of this 24 week study is to evaluate the spirometric lung function effect (trough FEV1) of Umeclidinium/Vilanterol 62.5/25 once daily compared to Tiotropium 18 mcg once daily along with safety assessments in subjects with COPD.
DOI: 10.3535/0t5-6gr-brw
title: siliciclastic rocks

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/jcj-ac1-fk8
title: Animalia

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.25934/00005468
title: The Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity: A 6-Month Double-Blind, Randomized, Placebo-Controlled Study With a 6-Month Open-Label Extension

description: The purposes of this study are to compare the effects of Topiramate and placebo on abdominal visceral fat accumulation at 6 months and to evaluate the safety of Topiramate for up to 12 months of continued treatment in male patients with abdominal obesity.
DOI: 10.3535/jch-45x-8yz
title: Animalia

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.25934/00002458
title: A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (30 mg QD and 60 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)

description: The purpose of this study is to assess the efficacy and safety of Dexlansoprazole modified release (MR) (30 mg once daily [QD] or 60 mg QD) compared to placebo in relief of daytime and nighttime heartburn over 4 weeks in subjects with symptomatic, nonerosive gastroesophageal reflux disease (GERD).
DOI: 10.25934/00003137
title: A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy

description: The purpose of this study is to study the safety and efficacy of TAK-438, once daily (QD), in participants with a history of gastric or duodenal ulcer requiring long-term NSAID therapy will be investigated.
DOI: 10.25934/00004970
title: TestStudy - Do not request - Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia

description: Duloxetine is FDA approved as pharmacological treatment for Fibromyalgia. The use of SSRIs has been endorsed by the 2013 Canadian guidelines. The data available for Escitalopram as a treatment modality for Fibromyalgia is limited, however small trials have demonstrated its efficacy. No head to head comparisons between escitalopram and duloxetine have been undertaken. We aim to conduct a single blind, randomized control trial to assess the comparative efficacy of duloxetine vs escitalopram in drug naive patients with newly diagnosed Fibromyalgia.
DOI: 10.25934/pr00004465.0
title: Available IPD datapackage for study 'A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)'

description: The purpose of this study is to assess the efficacy, the quality of life, and the safety of multiple dosing atomoxetine in Asian adult subjects with attention deficit/hyperactivity disorder (ADHD).
DOI: 10.25934/pr00009495
title: A PROSPECTIVE, PHASE 3, OPEN-LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE

description: The purpose of this phase 3 study is to investigate the efficacy and safety, including immunogenicity, thrombogenicity and hypersensitivity reactions, as well as pharmacokinetics (PK), health related quality of life (HRQoL) and pharmacoeconomics of prophylactic treatment with recombinant von Willebrand factor (rVWF) (vonicog alfa) in adult participants with severe von Willebrand disease (VWD).
DOI: 10.3535/174-mq5-05z
title: Animalia

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/b91-daa-48v
title: sedimentary rocks

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.25934/00001313
title: Study MEA117106: Mepolizumab vs. Placebo as add-on Treatment for Frequently Exacerbating COPD Patients

description: This is a multi-center, randomized, placebo-controlled, double-blind, parallel group trial evaluating mepolizumab 100 mg against placebo given every 4 weeks through subcutaneous (SC) injection. In severe COPD patients, sputum eosinophils levels are elevated similar as those seen in severe asthmatics. It is hypothesized that the reduction of eosinophils with mepolizumab in COPD patients would translate into a reduction of COPD exacerbations. The study will determine the reduction in exacerbations in subjects who are above and below the baseline blood eosinophil count of at least 150 cells/microlitres. The study will evaluate the efficacy and safety of mepolizumab on the frequency of moderate and severe exacerbations in COPD subjects at high risk of exacerbations, despite the use of optimized standard of care background therapy. Overall in this study, a total of 800 subjects will be randomised in 1:1 ratio to receive placebo or mepolizumab (100 milligram (mg)) administered SC. The total duration of this study will be approximately 62 weeks, consisting of a 1 to 2 week screening period, 52-week treatment period and 8-week follow-up period.
DOI: 10.25934/00001783
title: A part-randomised, single dose, open label, 6-way cross-over study to assess the relative systemic pharmacokinetics and absolute bioavailability of GW685698X and FP (1000mg) administered via Diskhaler® in healthy male subjects

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00004763.0
title: Available IPD datapackage for study 'A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS Methylphenidate (54 and 72 mg/Day) in Adults With Attention Deficit/Hyperactivity Disorder'

description: The purpose of this study is to evaluate the efficacy of 2 fixed dosages of Prolonged Release (PR) OROS methylphenidate (54 and 72 mg/day) compared with placebo in adult patients with attention deficit/hyperactivity disorder (ADHD).
DOI: 10.25934/pr00009494.0
title: Available datapackage for study 'A Multicentre, Randomised, Double-blind, 90-day Superiority Trial to Evaluate the Effect on Clinical Benefit, Safety and Tolerability of Once Daily Oral EMPagliflozin 10 mg Compared to Placebo, Initiated in Patients Hospitalised for acUte Heart faiLure (de Novo or Decompensated Chronic HF) Who Have Been StabilisEd (EMPULSE)'

description: This is a study in adults who are in hospital for acute heart failure. The purpose of this study is to find out whether starting to take a medicine called empagliflozin soon after first being treated in hospital helps people with acute heart failure. Participants are in the study for about 3 months. At the beginning, participants are still in hospital. Later, they visit the hospital about 3 times and get 1 phone call. Participants are put into 2 groups by chance. One group takes 1 empagliflozin tablet a day. The other group takes 1 placebo tablet a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine. Empagliflozin belongs to a class of medicines known as SGLT-2 inhibitors. It is used to treat type 2 diabetes. During the study, the doctors check whether participants have additional heart failure events like needing to go to the hospital again because of heart failure. The participants answer questions about how their heart failure affects their life. We then compare the results between the empagliflozin and placebo groups. The doctors also regularly check the general health of the participants.
DOI: 10.25934/pr00010645
title: An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

description: The purpose of this study is to assess the safety and tolerability of ASP8273 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). This study will also determine the pharmacokinetics (PK) of ASP8273, evaluate the potential inhibition of CYP3A4 by ASP8273 and the antitumor activity of ASP8273 as well as determine the effect of food on the bioavailability of ASP8273.
DOI: 10.25934/pr00010857
title: The TRISTARDS Trial - ThRombolysIS Therapy for ARDS A Phase IIb/III Operationally Seamless, Open-label, Randomised, Sequential, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Daily Intravenous Alteplase Treatment Given up to 5 Days on Top of Standard of Care (SOC) Compared With SOC Alone, in Patients With Acute Respiratory Distress Syndrome (ARDS) Triggered by COVID-19

description: This is a study in adults with severe breathing problems because of COVID-19. People who are in hospital on breathing support can participate in the study. The purpose of the study is to find out whether a medicine called alteplase helps people get better faster.The study has 2 parts. In the first part, participants are put into 3 groups by chance. Participants in 2 of the groups get 2 different doses of alteplase, in addition to standard treatment.Participants in the third group get standard treatment. In the second part of the study, participants are put into 2 groups by chance. One group gets alteplase and standard treatment. The other group gets only standard treatment. Alteplase is given as an infusion into a vein. In both study parts, treatments are given for 5 days. Doctors monitor patients and check whether their breathing problems improve. They compare results between the groups after 1 month.Participants are in the study for 3 months.
DOI: 10.3535/adn-d22-jr4
title: sedimentary rocks

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/d4d-ms8-5rq
title: Siltstone

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.25934/00003530
title: Phase I/II Trial of BIBW 2992 (Afatinib) in Treating Patients With Recurrent Glioblastoma Multiforme

description: Phase I Part: To determine the maximum tolerated dose (MTD) and pharmacokinetics of BIBW 2992 administered in combination with TMZ in patients with recurrent malignant gliomas (WHO Grade III and IV). Phase II Part: To estimate the efficacy and safety of BIBW 2992 monotherapy and BIBW 2992 / TMZ combination therapy compared to TMZ monotherapy (three treatment arms) in patients with recurrent GBM. To evaluate molecular determinants of response to BIBW 2992.
DOI: 10.25934/00003730
title: An Open Phase I Repeated Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

description: Primary: Maximum tolerated dose (MTD) Secondary: Determination of the pharmacokinetic profile of BI 2536. Assessment of safety and efficacy.
DOI: 10.25934/00006199
title: An Open, Non-randomised Multicentre Phase II Study to Assess the Efficacy and Tolerability of a 250 mg Monthly Dose of i.m. Applied Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

description: The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour response after 3 injections.
DOI: 10.25934/pr00010589
title: A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)

description: The objective of the study is to evaluate the efficacy and safety of a single sub-retinal injection of BIIB111 in participants with choroideremia (CHM).
DOI: 10.3535/9nw-0yv-t7d
title: †Trilobita

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/twz-jr9-0z8
title: Hyolithes sp.

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.25934/00004807
title: A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625)

description: This is a year-long clinical trial to evaluate the effectiveness and safety in women with Female Pattern Hair Loss (FPHL), comparing a new 5% minoxidil topical foam (MTF) formulation applied once a day versus the 2% minoxidil topical solution (MTS) applied twice a day. This clinical trial uses an objective measurement called Target Area Hair Count (TAHC) to evaluate if there is a change in the number of hairs in the area being examined after using the product for 24 weeks (and also after using the product for 12 Weeks and for 52 weeks). This trial will determine if the benefit of using either study product outweighs the risks.
DOI: 10.25934/00006773
title: A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study In Order To Investigate Safety And Efficacy Of CP- 690 550 In Subjects With Moderate To Severe Ulcerative Colitis.

description: The hypothesis of the study is that at least one dose of CP 690 550 is superior to placebo (inactive drug) in inducing remission in patients with moderate to severe ulcerative colitis.
DOI: 10.25934/pr00004133.0
title: Available IPD datapackage for study 'A Randomized, Double-Blind Study of Tomoxetine Hydrochloride, Methylphenidate Hydrochloride, and Placebo in Pediatric Outpatients with Attention Deficit/Hyperactivity Disorder'

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00004402.0
title: Available IPD datapackage for study 'A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride and Placebo in Child and Adolescent Outpatients With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder'

description: The purpose of this trial is to test the effectiveness of atomoxetine in treating symptoms of ODD in children with ADHD and ODD.
DOI: 10.3535/gp4-tap-etl
title: †Proetidae

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.25934/00002444
title: A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg Once-Daily (QD) and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)

description: The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
DOI: 10.25934/00005696
title: A Randomized, Placebo Controlled, Double-blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate, Compared to Methotrexate Monotherapy, in Patients With Active Rheumatoid Arthritis

description: This study evaluated the efficacy and safety of rituximab in patients with active rheumatoid arthritis (RA).
DOI: 10.25934/pr00008253
title: A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine

description: The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.
DOI: 10.3535/1h8-xl1-yhe
title: †Diplotrypa petropolitana Nicholson, 1879

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/bjx-hq3-7th
title: siliciclastic rocks

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.25934/pr00008428.0
title: Type 1 Diabetes EXercise Initiative: The Effect of Exercise on Glycemic Control in Type 1 Diabetes Study

description: Brief Summary: The Type 1 Diabetes Exercise Initiave (T1-DEXI) was an observational study of adults living with type 1 diabetes in the U.S., conducted remotely outside of clinics, designed to develop a better understanding of the effects of different levels of exercise intensity and duration on glycemic control during and after exercise across a wide range of patient characteristics.  This dataset incorporates aggregated data around exercise events including pertinent diabetes management information (insulin and continuous glucose monitoring data), self-reported and objectively measured physical activity levels (Polar H10 sensor and Verily Study Watch), self-reported stress levels and life-event data such as the timing and composition of meals (Remote Food Photography Method). Genotyping, completed for a subset of participants, may help researchers understand how variations in DNA may be associated with exercise, diabetes, and glycemic response to exercise.
DOI: 10.3535/2sn-fla-e3x
title: Tabulata

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3535/2vq-yej-kl7
title: Pyrite

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.